| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-06-21 | MeiraGTx (USA - NY) | validation of a production plant | Rare diseases - Genetic diseases | Validation of a production plant | ||
| 2018-06-19 | Poietis (France) Prometheus, division of skeletal tissue engineering of KU Leuven (Belgium) | 3D bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration. | research - development - R&D | Technology - Services - Regenerative medicine | Research agreement | |
| 2018-06-18 | Mylan (USA - PA) Lupin (India) | etanercept biosimilar | rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis | commercialisation | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases | Commercialisation agreement |
| 2018-06-11 | RegenXBio (USA - MD) Avexis (USA - MA) | products to treat Spinal Muscular Atrophy (SMA) using NAV rAAV9 vectors | spinal muscular atrophy | licensing | Rare diseases - Genetic diseases - Neuromuscular diseases | Milestone |
| 2018-06-08 | Amicus Therapeutics (USA - NJ) | member of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-06-07 | Orchard Therapeutics (UK) | member of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-06-07 | Sarepta Therapeutics (USA - MA) | chief medical officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-06-05 | Iontas (UK) LG Chem (South Korea) | therapeutic antibodies targeting undisclosed targets | collaboration - research - development | Cancer - Oncology | Development agreement | |
| 2018-06-05 | InflaRx (Germany) | opening of new premises | Inflammatory diseases | Opening of new premises | ||
| 2018-06-05 | Ideaya Biosciences (USA - CA) | head of operations, vice president | nomination | Cancer - Oncology | Nomination | |
| 2018-06-04 | Sarepta Therapeutics (USA - MA) | vice-president | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-06-04 | Allogene Therapeutics (USA - CA) | chief technical officer | nomination | Cancer - Oncology | Nomination | |
| 2018-05-31 | Arix Bioscience (UK) Evotec (Germany) Fred Hutchinson Cancer Research Center (USA - WA) | LAB591 to build new companies in cancer and infectious diseases | cancer, infectious diseases | collaboration | Cancer - Oncology - Infectious diseases | Collaboration agreement |
| 2018-05-30 | Celltrion Healthcare (South Korea) Yonsei University Health System (South Korea) | Fc-saxatilin | ischemic stroke | development - licensing | Cerebrovascular diseases | Development agreement |
| 2018-05-30 | Five Prime Therapeutics (USA - CA) Roche (Switzerland) | immunohistochemistry (IHC) companion diagnostic assays for use with bemarituzumab (FPA144), and FPA150 | tumors overexpressing FGFR2b | development | Cancer - Oncology | Development agreement |
| 2018-05-30 | BioMolecular Therapeutics (BMT) (Republic of Korea) Samyang (Republic of Korea) | asymmetric siRNA (asiRNA) | undisclosed | research | undisclosed | Research agreement |
| 2018-05-30 | Allogene Therapeutics (USA - CA) | board of directors | nomination | Cancer - Oncology | Nomination | |
| 2018-05-30 | Gemini Therapeutics (USA) | chief business officer, chief medical officer | nomination | Nomination | ||
| 2018-05-29 | BioNTech (Germany) | nomination | Cancer - Oncology - Infectious diseases | Nomination | ||
| 2018-05-25 | Imcheck Therapeutics (France) | chairman of the board | nomination | Cancer - Oncology - Autoimmune diseases | Nomination |
